



## Original article

# Simultaneous enantioseparation and simulation studies of atenolol, metoprolol and propranolol on Chiralpak<sup>®</sup> IG column using supercritical fluid chromatography



Pranav A. Pandya, Priyanka A. Shah, Pranav S. Shrivastav\*

Department of Chemistry, School of Sciences, Gujarat University, Ahmedabad, 380009, India

## ARTICLE INFO

## Article history:

Received 17 May 2020

Received in revised form

13 December 2020

Accepted 15 December 2020

Available online 21 December 2020

## Keywords:

Enantioseparation

Supercritical fluid chromatography

 $\beta$ -blockersChiralpak<sup>®</sup> IG column

Molecular docking

Binding energy

## ABSTRACT

Enantioseparation of three  $\beta$ -blockers, i.e., atenolol, metoprolol and propranolol, was studied on amylose tris(3-chloro-5-methylphenylcarbamate) immobilized chiral stationary phase using supercritical fluid chromatography (SFC). The effect of organic modifiers (methanol, isopropanol and their mixture), column temperature and back pressure on chiral separation of  $\beta$ -blockers was evaluated. Optimum chromatographic separation with respect to resolution, retention, and analysis time was achieved using a mixture of CO<sub>2</sub> and 0.1% isopropyl amine in isopropanol: methanol (50:50, V/V), in 75:25 (V/V) ratio. Under the optimized conditions, the resolution factors ( $R_s$ ) and separation factors ( $\alpha$ ) were greater than 3.0 and 1.5, respectively. Further, with increase in temperature (25–45 °C) and pressure (100–150 bars) there was corresponding decrease in retention factors ( $k$ ),  $\alpha$  and  $R_s$ . However, a reverse trend ( $\alpha$  and  $R_s$ ) was observed for atenolol with increase in temperature. The thermodynamic data from van't Hoff plots revealed that the enantioseparation was enthalpy driven for metoprolol and propranolol while entropy driven for atenolol. To understand the mechanism of chiral recognition and the elution behavior of the enantiomers, molecular docking studies were performed. The binding energies obtained from simulation studies were in good agreement with the elution order found experimentally and also with the free energy values. The method was validated in the concentration range of 0.5–10  $\mu\text{g/mL}$  for all the enantiomers. The limit of detection and limit of quantitation ranged from 0.126 to 0.137  $\mu\text{g/mL}$  and 0.376–0.414  $\mu\text{g/mL}$ , respectively. The method was used successfully to analyze these drugs in pharmaceutical preparations.

© 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Separation of enantiomers to obtain pure chiral drugs is a subject of intense research and is now gaining priority, especially in the pharmaceutical industry [1–3]. There are several reports that show marked differences in the pharmacodynamics and pharmacokinetics of enantiomers of the drug, wherein one of the enantiomers has the desired pharmacologic effect, while the other is either inactive or is associated with undesirable side effects [1,4]. This difference in the pharmacokinetics is mainly due to stereoselective drugs binding (generally with plasma proteins), absorption, clearance, and excretion. Thus, there is a constant need to develop

methods both analytical and preparative that have high resolution power and good efficiency for chiral purity testing and pharmacokinetic studies [4,5].

$\beta$ -adrenoceptor antagonists or  $\beta$ -blockers are used for the treatment of several cardiovascular diseases, including hypertension, ischemic heart disease, and migraines. They are mainly administered and marketed as racemic mixtures. However, the pharmacological activity resides with the *S*-enantiomer due to its greater stereoselective affinity towards  $\beta$ -receptors. The *R*-enantiomers are either pharmacologically inactive or toxic [6–8]. Atenolol is a second-generation  $\beta$ -blocker used in the treatment of hypertension, angina pectoris, and acute myocardial infarction [9]. Metoprolol is a  $\beta_1$  selective adrenergic blocker used in the management of ischemic heart disease, heart failure and hypertension [8]. Propranolol, a nonselective  $\beta$ -blocker, is used to prevent migraines, and for the treatment of hypertension and anxiety [7].

Peer review under responsibility of Xi'an Jiaotong University.

\* Corresponding author.

E-mail address: [pranav\\_shrivastav@yahoo.com](mailto:pranav_shrivastav@yahoo.com) (P.S. Shrivastav).

Several analytical techniques have been used for enantiomeric separation of these drugs, namely, thin layer chromatography [10], surface enhanced Raman scattering [11], counter current chromatography [12], electrochromatography [13,14], capillary electrophoresis [15–18], high performance liquid chromatography (HPLC) [9,19–23], liquid chromatography-tandem mass spectrometry (LC-MS/MS) [24–29], and supercritical fluid chromatography (SFC) [30–33]. Among different chiral stationary phases (CSPs), polysaccharide (cellulose or amylose) based phases are the most widely used with these techniques [20,21,23,32,33]. Nikolai et al. [24] have quantified atenolol, metoprolol and propranolol by LC-MS/MS using Chirobiotic V vancomycin-based chiral column within 20 min. Recently, Li et al. [23] reported enantiomeric separation of six  $\beta$ -blockers on Chiralpak IB column using HPLC and used molecular docking technique to understand the mechanism of chiral recognition. However, there are very few SFC based methods that report enantioseparation of the drugs studied in the present work. Svan et al. [32] employed Chiralpak IB column for the chiral separation of atenolol, metoprolol, propranolol and the zwitterionic metoprolol acid using SFC-MS/MS.

As evident from the literature, chiral HPLC is the technique of choice for separations of  $\beta$ -blockers. However, due to some inherent limitations of HPLC such as higher solvent consumption and long analysis time, SFC presents an alternative approach using environment friendly mobile phases. It employs relatively less toxic and non-polar  $\text{CO}_2$  as the basic component of the mobile phase, and utilizes a majority of the CSP used in HPLC. Further, the advantage of SFC over HPLC is that column efficiency does not decrease with an increase in flow rate at the same rate as seen in HPLC. Thus, one can operate SFC at a higher linear velocity relative to HPLC, resulting in shorter analysis time [34,35]. In one such report, much better enantioresolution and shorter analysis time were found with SFC compared to HPLC on Chiral Art Cellulose-SB column for these drugs [33]. Thus far, there are no reports on the use of Chiralpak<sup>®</sup> IG column with amylose tris(3-chloro-5-methylphenylcarbamate) immobilized chiral stationary phase for enantioseparation of atenolol, metoprolol and propranolol.

Thus, the objectives of the present work were 1) to optimize conditions for simultaneous enantioseparation of atenolol, metoprolol and propranolol on Chiralpak<sup>®</sup> IG column in a single analysis and 2) to study the thermodynamic aspects of chiral separation for understanding the mechanism of chiral recognition. Type of polar modifier in the mobile phase greatly influences the interaction of the analyte with the stationary phase and thereby the resolution of chiral substances. It can alter the solvent strength and mobile phase density, can compete with the analytes for adsorption sites, and might induce some changes in the stationary phase structure [36]. Further, molecular docking studies were performed to understand the binding energy required to interact with the CSP and correlation with the experimentally evaluated thermodynamic parameters. The validated method was also used to analyze the drugs in their tablet formulations.

## 2. Experimental

### 2.1. Chemicals and reagents

Reference standards of *rac*-atenolol ( $\geq 98\%$ ), *rac*-propranolol hydrochloride ( $\geq 99\%$ ), *rac*-metoprolol tartrate ( $\geq 99\%$ ) were procured from Sigma Aldrich Chemicals Pvt. Ltd. (Bangalore, India), while *S*(–)-atenolol, *R*(+)-atenolol, *S*(–)-metoprolol, *R*(+)-metoprolol, *S*(–)-propranolol, *R*(+)-propranolol enantiomers of purity  $\geq 98.0\%$  were purchased from Toronto Research Chemicals Inc. (Ontario, Canada). HPLC grade methanol, isopropanol and isopropylamine (99%) were acquired from Sigma Aldrich Chemicals

Pvt. Ltd. (Bangalore, India). Liquid carbon dioxide ( $\text{CO}_2$ , 99.9%) was procured from SICCIL Industrial Gases Limited (Baroda, India).

### 2.2. Instrumental and chromatographic conditions

Chromatographic analysis for the  $\beta$ -blockers was carried out on a Waters SFC Investigator system (Milford, MA, USA) equipped with a fluid delivery module, an autosampler with partial loop volume injection system, a backpressure regulator, column oven and photodiode array (PDA) detector. The ChromScope v1.2.1 software was used for data handling. All six enantiomers were separated on Chiralpak<sup>®</sup> IG column (250 mm  $\times$  4.6 mm, 5  $\mu\text{m}$ ) packed with amylose tris(3-chloro-5-methylphenylcarbamate) immobilized with silica gel. The temperature of the column oven was 40 °C. The mobile phase was a mixture of  $\text{CO}_2$  and 0.1% isopropyl amine in isopropanol: methanol (50:50, V/V), in 75:25 (V/V) ratio and was pumped at a constant flow rate of 4.0 mL/min. The injection volume was 10  $\mu\text{L}$  and detection wavelength was set at 220 nm. The backpressure of the system was 100 bars. The sample cooler temperature was kept at 10 °C. For optical rotation measurement, MCP 5100 Modular Circular Polarimeter, from Anton Paar India Pvt. Ltd. (Haryana, India) was used with sodium source, wavelength 589 nm.

### 2.3. Preparation of stock solutions and calibrators


Separate standard stock solutions (2500  $\mu\text{g}/\text{mL}$ ) of *rac*-atenolol, *rac*-propranolol hydrochloride, *rac*-metoprolol tartrate, *S*(–)-atenolol, *R*(+)-atenolol, *S*(–)-metoprolol, *R*(+)-metoprolol, *S*(–)-propranolol, and *R*(+)-propranolol were prepared in methanol. Their working solutions (500  $\mu\text{g}/\text{mL}$ ) were prepared in methanol using their respective standard stock solutions. For construction of linear curves, calibration standards (CSs) of enantiomers were prepared from their working solutions to obtain solutions with the following concentrations, 0.50, 1.00, 2.00, 3.00, 4.00, 6.00, 8.00 and 10.0  $\mu\text{g}/\text{mL}$ , respectively. Similarly, quality control (QC) samples were prepared at 1.50  $\mu\text{g}/\text{mL}$  (low), 5.00  $\mu\text{g}/\text{mL}$  (medium), and 9.00  $\mu\text{g}/\text{mL}$  (high), respectively.

### 2.4. Assay of tablet formulation

In order to evaluate the content of pharmaceutical formulations, 20 tablets each of Betaloc<sup>®</sup> 50 mg (metoprolol tartrate from Astra Zeneca Pharma India Ltd., Ahmedabad, India), Betacap<sup>®</sup> 10 mg (propranolol hydrochloride from Sun Pharmaceutical Industries Ltd., Mumbai, India) and Betacard<sup>®</sup> 50 mg (atenolol from Torrent Pharmaceuticals Ltd., Ahmedabad, India) were weighed and ground to fine powder. An amount equivalent to 50 mg metoprolol, 10 mg propranolol and 50 mg atenolol was taken into separate 50 mL volumetric flask containing 25 mL methanol. Thereafter, the solutions were sonicated for 30 min and then made up to volume with methanol. Their working solutions (10  $\mu\text{g}/\text{mL}$ ) were prepared by diluting the stock solution with methanol. For analysis, 10  $\mu\text{L}$  was applied to the column in six replicates. Peak area for all the enantiomers was determined at 220 nm and the amount of each enantiomer present in the tablets was estimated from their regression equations.

### 2.5. Molecular docking study

Molecular docking of the enantiomers was done with an Intel dual CPU (2.00 GHz) on Windows 10 operating system. To sketch the structures of the enantiomers and the amylose derivatized CSP, Marwin Sketch software was utilized [37]. The structures were sparked to 3D and saved in a PDB file. The structure of



**Fig. 1.** SFC chromatograms showing effect of organic modifiers (A) isopropanol, (B) methanol, and (C) isopropanol:methanol (50:50, V/V) on the separation of enantiomers; (D) chemical structures of enantiomers. Column: Chiralpak® IG; mobile phase: CO<sub>2</sub>: 0.1% isopropyl amine in organic modifier (80:20, V/V); temperature: 40 °C; back pressure: 100 bars; detection wavelength: 220 nm; flow rate: 4 mL/min.

amylose derivatized CSP was docked using Auto Dock Tools (ADT) 4.2 by handing over Gasteiger charges, integrating nonpolar hydrogen atoms, and saving in PDBQT file format. The docking

permitted all the rotatable bonds of the ligands as a rotatable and rigid receptor [38]. The isomers were edited and saved in the PDBQT format using the same tool. The lattice box size used was

70 Å × 80 Å × 70 Å with spacing of 0.375 Å. Auto Dock Vina software was then applied to acquire the binding energy/affinity between the receptor, amylose tris(3-chloro-5-methylphenylcarbamate) and the enantiomer. The output file was then opened in Discovery Studio Visualizer (Dassault systems Biovia Corporation) for virtual screening, molecular docking, to study the binding site and to estimate the interaction and the bond length between stationary phase and the enantiomer.

### 3. Results and discussion

#### 3.1. Effect of organic modifier

Initially, the effect of organic modifier (methanol, isopropanol and their mixture) was studied on Chiralpak® IG column, having an immobilized amylose tris(3-chloro-5-methylphenylcarbamate) stationary phase. The experiments were performed using CO<sub>2</sub> with 20% organic modifier containing 0.1% isopropylamine at 40 °C and 100 bars back pressure. The basic additive, isopropylamine, provided good resolution, peak shape and sufficient response for the isomers as compared to diethylamine or triethylamine which is commonly used in SFC. All three organic modifiers afforded complete separation of enantiomer pairs individually; however, it was not possible to separate simultaneously all six enantiomers in a single run within an optimum analysis time in methanol and isopropanol, respectively. Though these drugs are not available in combination, it is advantageous to have one single method rather than three separate methods/elution conditions to analyze these drugs.

As shown in Fig. 1, the *S*(−) isomers of metoprolol and propranolol co-eluted in isopropanol and methanol, and *R*(+) isomers of atenolol and propranolol in isopropanol. Nevertheless, all the enantiomers were baseline resolved in methanol-isopropanol (50:50, V/V) mixture. Besides, the elution order of enantiomers remained unchanged (*S*(−) ahead of *R*(+) isomer) for all the modifiers. This was confirmed by collecting the fractions and measuring their optical rotation and also from their individual reference standards. Furthermore, there was greater retention of enantiomers with methanol compared to isopropanol and their mixture. On the other hand, the retention was relatively less with isopropanol, especially for the *S*(−) isomers of metoprolol and propranolol (Table S1). However, based on the criterion of separation factor ( $\alpha \geq 1.5$ ) and resolution factor ( $R_s \geq 1.5$ ), together with simultaneous separation of all six enantiomers, a mixture of methanol:

isopropanol (50:50, V/V) was considered in the entire work.


The effects of different proportions (15, 20, 25, 30 and 35) of methanol:isopropanol (50:50) on retention time, retention factors (*k*),  $\alpha$  and  $R_s$  of the enantiomers are given in Table S2. The retention of enantiomers decreased with increase in organic modifier content, which is due to the increase in the solvating power of the CO<sub>2</sub> based mobile phase. Fig. 2A shows the variation in ln *k* values with percentage of methanol:isopropanol (50:50, V/V) in the mobile phase. As evident, there was greater retention of *R*(+) isomer than that of *S*(−) isomer for all the three  $\beta$ -blockers. A similar downward trend was observed with the separation factors ( $\alpha$ ) as shown in Fig. 2B. However, for atenolol which is more polar than the other  $\beta$ -blockers, this decrease was more prominent and was affected more with increase in organic modifier content in the mobile phase.

#### 3.2. Effect of back pressure


It is well known that the solvation ability of supercritical CO<sub>2</sub> increases with increase in back pressure, and thus helps in rapid elution of the analytes from the column [39]. The effect of back pressure on enantioseparation was studied at 100, 125 and 150 bars. The retention of the enantiomers decreased with increase in back pressure for all the  $\beta$ -blockers (Table S3). A similar trend was observed with the resolution factors, with no major change in separation factors. Further, the decrease in retention of *S*-isomers was much less than that of the *R*-isomers with increase in back pressure. The  $R_s$  values decreased from 5.68 to 5.01, 6.83–6.02 and 3.48–3.26 for the enantiomers of metoprolol, propranolol and atenolol, respectively at 40 °C. This trend can be related to greater solvation ability of supercritical CO<sub>2</sub> with increasing back pressure leading to faster elution of the enantiomers.

#### 3.3. Effect of temperature on the enantioseparation

Temperature plays a significant role in enantiomeric separations as reported in several studies [39,40]. It can produce changes in retention time, selectivity, and resolution. The effect of temperature was studied in the sub and supercritical region from 25 °C to 45 °C in 5 °C increments (Table S3). Similar to the back pressure effect, with increase in temperature the retention of the enantiomers decreased for all three drugs at 100 bars as shown in Fig. 3. However, it is worth noting that there was reversal in the elution order in the case of *R*(+)-metoprolol and *R*(+)-atenolol in the sub critical region at 25 °C and 30 °C. Under typical supercritical conditions, the




**Fig. 2.** Variation of (A) retention factors (ln *k*) and (B) separation factors (ln  $\alpha$ ) for enantiomers of atenolol, metoprolol and propranolol with different percentages of organic modifier. Mobile phase: CO<sub>2</sub>: 0.1% isopropyl amine in isopropanol: methanol (50:50, V/V). Column: Chiralpak® IG; temperature: 40 °C; back pressure: 100 bars; detection wavelength: 220 nm; flow rate: 4 mL/min.  $\alpha_1$ ,  $\alpha_2$ , and  $\alpha_3$ : separation factors between enantiomers of metoprolol ( $\alpha_1$ ), propranolol ( $\alpha_2$ ), and atenolol ( $\alpha_3$ ). A: atenolol; M: metoprolol; P: propranolol.



**Fig. 3.** SFC chromatograms showing effect of temperature (A) 25 °C, (B) 30 °C, (C) 35 °C, (D) 40 °C, and (E) 45 °C on the enantioseparation of the drugs. Column: Chiralpak® IG; mobile phase: a mixture of CO<sub>2</sub> and 0.1% isopropyl amine in isopropanol:methanol (50:50, V/V), in 75:25 (V/V) ratio; back pressure: 100 bars; detection wavelength: 220 nm; flow rate: 4 mL/min.





**Fig. 4.** van't Hoff plots of retention factors ( $\ln k$ ) of atenolol, metoprolol and propranolol enantiomers versus temperature ( $1000/T$ ) at different back pressures (A) 100 bars, (B) 125 bars, and (C) 150 bars. Column: Chiralpak<sup>®</sup> IG; mobile phase: a mixture of CO<sub>2</sub> and 0.1% isopropyl amine in isopropanol:methanol (50:50, V/V), in 75:25 (V/V) ratio; detection wavelength: 220 nm; flow rate: 4 mL/min.

**Table 1**  
Thermodynamic parameters for enantiomers on Chiralpak<sup>®</sup> IG column under different back pressures.

Stereoisomer	100 bar			125 bar			150 bar		
	$\Delta G$ (kJ/mol)	$\Delta H$ (kJ/mol)	$\Delta S$ (J/mol K)	$\Delta G$ (kJ/mol)	$\Delta H$ (kJ/mol)	$\Delta S$ (J/mol K)	$\Delta G$ (kJ/mol)	$\Delta H$ (kJ/mol)	$\Delta S$ (J/mol K)
S(–)-metoprolol	–1.290	–4.232	–9.872	–1.221	–4.248	–10.16	–1.171	–3.385	–7.429
R(+)-metoprolol	–3.989	–11.47	–25.12	–3.928	–13.30	–31.46	–3.881	–13.93	–33.73
S(–)-propranolol	–2.464	–6.448	–13.37	–2.449	–8.031	–18.73	–2.409	–8.296	–19.76
R(+)-propranolol	–4.800	–12.09	–24.46	–4.781	–14.57	–32.87	–4.726	–14.88	–34.07
S(–)-atenolol	–2.864	–6.260	–11.40	–2.871	–7.158	–14.38	–2.844	–7.358	–15.15
R(+)-atenolol	–4.120	–4.878	–2.544	–4.085	–4.751	–2.235	–3.960	–5.008	–3.516

retention should increase with increase in temperature as the fluid density decreases, which results in decrease in the fluid elution strength [39]. However, to explain the observed behavior, at higher temperature the solubility of the enantiomers increased in the mobile phase due to decrease in cohesiveness of the fluid, leading to decreased retention. This behavior is typically observed in HPLC separations.

The relation between the retention factor ( $k$ ) and the temperature is expressed by the van't Hoff equation,

$$\ln k = -\Delta H/RT + \Delta S/R + \ln(1/\beta) \quad (1)$$

where  $\Delta H$  and  $\Delta S$  are the standard molar enthalpy and molar entropy for transfer of analyte from the mobile phase to the stationary phase, respectively.  $\beta$  represents the phase ratio and  $R$  is the ideal gas constant (8.314 J/mol K). The plots of logarithm of retention factors,  $\ln k$  versus temperature ( $1000/T$ ) at different back pressures are shown in Fig. 4. These plots were almost linear for all the enantiomers, which indicates no significant change in the phase ratio due to change in the density at different temperatures. The


standard molar free energy ( $\Delta G$ ),  $\Delta H$  and  $\Delta S$  values at different back pressures for the isomers are summarized in Table 1. The  $\Delta G$  values were negative for all the enantiomers at different pressures and also at different temperatures (Table S4). Likewise,  $\Delta H$  and  $\Delta S$  values were also negative, which indicates that the transfer of enantiomers from the mobile phase to the stationary phase was enthalpy driven.

From Fig. 5, it can be observed that the selectivity increases with decrease in temperature for metoprolol and propranolol at constant pressure, whereas a slight decrease in selectivity was found for atenolol. The relationship between the separation factor and temperature can be expressed as

$$\ln(\alpha) = -\Delta\Delta H/RT + \Delta\Delta S/R \quad (2)$$

$$\ln(\alpha) = -\Delta\Delta G/RT \quad (3)$$

where,  $\Delta\Delta H$  and  $\Delta\Delta S$  represent differential enthalpy and entropy, respectively. The plot of  $\ln(\alpha)$  versus  $1/T$  is linear if the enantioselective separation does not change over the temperature range



**Fig. 5.** Changes in the separation factors ( $\ln \alpha$ ) of enantiomers with temperature ( $1/T$ ) at three different back pressures (A) 100 bars, (B) 125 bars, and (C) 150 bars. Column: Chiralpak<sup>®</sup> IG; mobile phase: a mixture of CO<sub>2</sub> and 0.1% isopropyl amine in isopropanol:methanol (50:50, V/V), in 75:25 (V/V) ratio; detection wavelength: 220 nm; flow rate: 4 mL/min.  $\ln \alpha_1$ ,  $\ln \alpha_2$ , and  $\ln \alpha_3$  represent separation factors between enantiomers of metoprolol, propranolol, and atenolol, respectively.



**Table 3**  
Molecular docking results for enantiomers of  $\beta$ -blockers.

Enantiomer	Binding energy (kJ/mol)	Ligand efficiency	No. of interactions	Intermolecular bonding interaction		Binding site		Bond length/ distance (Å)	$\Delta E_{R-S}$ (kJ/mol)
				Category	Type	Enantiomer	CSP		
S(-)-atenolol	-4.37	-0.23	4	H-bond	Conventional H-bond	Ph-O-C	H of the -CO-NH-	3.00	0.63
				H-bond	Conventional H-bond	C=O of NH <sub>2</sub> -CO-Ph	H of the -CO-NH-	2.92	
				H-bond	Conventional H-bond	H of NH <sub>2</sub> -CO-Ph	CO of the -CO-NH-	3.25	
				H-bond	Hydrogen bond	H of C-CH-C	CO of the -CO-NH-	3.03	
R(+)-atenolol	-5.00	-0.26	3	H-bond	Conventional H-bond	H of C-NH-C	CO of the -CO-NH-	2.84	
				H-bond	Conventional H-bond	H of NH <sub>2</sub> -CO-Ph	CO of the -CO-NH-	2.92	
				Hydrophobic bond	Alkyl-alkyl bond	CH <sub>3</sub> -CH-CH <sub>3</sub>	CH <sub>3</sub> of phenyl ring	3.40	
S(-)-metoprolol	-3.35	-0.18	2	H-bond	$\pi$ -donor H-bond	$\pi$ -electrons of the phenyl ring	H of the -CO-NH-	3.26	1.53
				Other	$\pi$ -lone pair	$\pi$ -electrons of the phenyl ring	Lone pair on CO of the -CO-NH-	2.98	
R(+)-metoprolol	-4.88	-0.25	5	H-bond	Hydrogen bond	H of -CO-CH <sub>3</sub>	CO of the -CO-NH-	3.33	
				H-bond	Hydrogen bond	H of -CO-CH <sub>3</sub>	CO of the -CO-NH-	3.35	
				Hydrophobic	$\pi$ -sigma	CH <sub>3</sub> -CH-CH <sub>3</sub>	$\pi$ -electrons of the phenyl ring	3.71	
				Hydrophobic	$\pi$ -alkyl	$\pi$ -electrons of the phenyl ring	CH <sub>3</sub> of phenyl ring	4.38	
				Hydrophobic	$\pi$ -alkyl	$\pi$ -electrons of the phenyl ring	CH <sub>3</sub> of phenyl ring	5.33	
S(-)-propranolol	-3.95	-0.21	4	Hydrophobic	$\pi$ -sigma	$\pi$ -electrons of naphthyl ring	CH <sub>3</sub> of phenyl ring	3.50	1.36
				Hydrophobic	$\pi$ - $\pi$ stacked	$\pi$ -electrons of naphthyl ring	$\pi$ -electrons of the phenyl ring	4.39	
				Hydrophobic	$\pi$ -alkyl	$\pi$ -electrons of naphthyl ring	CH <sub>3</sub> of phenyl ring	5.03	
				Hydrophobic	$\pi$ -alkyl	$\pi$ -electrons of naphthyl ring	CH <sub>3</sub> of phenyl ring	4.01	
R(+)-propranolol	-5.31	-0.29	5	H-bond	Hydrogen bond	H of CH <sub>3</sub> -CH-CH <sub>3</sub>	CO of the -CO-NH-	3.27	
				Hydrophobic	$\pi$ -sigma	$\pi$ -electrons of naphthyl ring	CH <sub>3</sub> of phenyl ring	3.41	
				Hydrophobic	$\pi$ -sigma	$\pi$ -electrons of naphthyl ring	CH <sub>3</sub> of phenyl ring	3.94	
				Hydrophobic	$\pi$ - $\pi$ stacked	$\pi$ -electrons of naphthyl ring	$\pi$ -electrons of the phenyl ring	4.32	
				Hydrophobic	$\pi$ -alkyl	CH <sub>3</sub> -CH-CH <sub>3</sub>	$\pi$ -electrons of the phenyl ring	5.27	

CSP: chiral stationary phase (Chiralpak® IG).

studied. The plots were linear for all enantiomers, which indicates that a temperature value (isoelution temperature,  $T_{iso}$ ) exists at which the isomers co-elute. The separation is enthalpy driven below  $T_{iso}$  and the separation factors can increase with decrease in temperature. Above  $T_{iso}$ , the chiral separation is entropy driven and the separation factors are expected to increase with increase in temperature [40]. From regression lines (Fig. 5), the values of  $\Delta\Delta H$ ,  $\Delta\Delta S$  and  $T_{iso}$  were computed and are presented in Table 2. The values of  $\Delta\Delta H$  and  $\Delta\Delta S$  were negative for metoprolol and propranolol while the reverse was found for atenolol at different pressures. Further, with increase in back pressure there was an increase in the absolute values of  $\Delta\Delta H$  and  $\Delta\Delta S$ . The absolute values of  $\Delta\Delta H/RT$  were greater than  $\Delta\Delta S/RT$  for metoprolol and propranolol, which suggests that the separation process was enthalpy controlled. The  $T_{iso}$  values were above the working range of temperature for metoprolol and propranolol and can be improved by decreasing the temperature. On the other hand, the  $T_{iso}$  values were below the temperature range studied for atenolol and thus the

enantioseparation was entropy driven. This thermodynamic data were analyzed in terms of enthalpy-entropy compensation. The plot of  $\Delta\Delta H$  versus  $\Delta\Delta S$  was a straight line, which shows enthalpy-entropy compensation for enantioselectivity (Fig. S1).

#### 3.4. Molecular docking studies with chiral stationary phases

To study the elution pattern and understand the chiral recognition mechanism, molecular docking was performed using Auto Dock Tools (ADT) 4.2 software. This tool facilitates prediction of most favored orientation of small molecules to interact with the stationary phase. The binding energies and the bond lengths of different interaction modes can be estimated with reasonable accuracy [22,23]. Further, it can help in understanding the elution behavior of the enantiomers based on binding energies. The binding energies are a result of different intermolecular interactions such as H-bonding and Van der Waals,  $\pi$ - $\pi$  interactions and dipole-dipole interactions. More negative values reflect greater stability of



**Table 4**  
Comparison of chromatographic methods developed for simultaneous separation of atenolol, metoprolol and propranolol.

Sr. No.	Technique	Column	Mobile phase composition	Run time (min)	Thermodynamic study & molecular modeling	Application	Refs.
1	Capillary electrophoresis	Fused silica capillary (40 cm length × 50 μm)	–	32	Yes; yes	–	[15]
2 <sup>a</sup>	HPLC-UV	Vancomycin-bonded column (150 mm × 2.1 mm, 5 μm)	Methanol:triethylamine:glacial acetic acid in the volume ratio of 100:0.01:0.02 (V/V/V)	~20	Yes; yes	–	[30]
3 <sup>b</sup>	HPLC-UV	Chiralpak IB (250 mm × 4.6 mm, 5 μm)	<i>n</i> -hexane-ethanol/isopropanol-0.1% diethylamine	~35	–; yes	–	[31]
4	HPLC-MS/MS	Chirobiotic V vancomycin-based chiral column (250 mm × 4.6 mm, 5 μm)	Methanol:water with 0.1% triethylammonium acetate adjusted to pH 4.0 with acetic acid (90:10, V/V)	20	–; –	Quantification in wastewater treatment plant influents and effluents	[32]
5 <sup>c</sup>	SFC-MS/MS	Chiralpak <sup>®</sup> IB-3 (100 mm × 4.6 mm, 3 μm)	82% carbon dioxide and 18% of a modifier, consisting of methanol & 0.5% (V/V) of the additives trifluoroacetic acid (TFA) & ammonia (NH <sub>3</sub> ) in a 2:1 M ratio	10	–; –	Monitored the enantiomeric fraction change over time in a laboratory scale wetland degradation study	[40]
6	SFC-PDA	Chiralpak <sup>®</sup> IG (250 mm × 4.6 mm, 5 μm)	Mixture of CO <sub>2</sub> and 0.1% isopropyl amine in isopropanol:methanol (50:50, V/V), in 75:25 (V/V) ratio	6	Yes; yes	Quantification in pharmaceutical formulations	PM

<sup>a</sup>Together with amlodipine, venlafaxine & fluoxetine; <sup>b</sup>together with bevantolol, cartelol & esmolol; <sup>c</sup>in presence of zwitterionic metoprolol acid; PM: present method.

enantiomer-CSP binding. The 3D interaction of the enantiomers with the chiral stationary phase is shown in Fig. 6. The CSP has >C=O, –NH– and a phenyl ring with alkyl and chloro groups, while the enantiomers have carbamoyl group (only in atenolol), –OH, –O–, >C=O, secondary amine, isopropyl groups and aromatic ring systems (phenyl and naphthyl). As such they can interact via H-bonding,  $\pi$ - $\pi$  interactions, and hydrophobic interactions. The binding energy, ligand efficiency, number and type of intermolecular interactions with bond lengths are presented in Table 3. The binding energy (kJ/mol) for the enantiomers followed the order: *S*(–)-metoprolol (–3.35)>*S*(–)-propranolol (–3.95)>*S*(–)-atenolol (–4.37)>*R*(+)-metoprolol (–4.88)>*R*(+)-atenolol (–5.00)>*R*(+)-propranolol (–5.31). It can be inferred that *R*(+)-propranolol formed the strongest interaction with the CSP, while *S*(–)-metoprolol the weakest. Additionally, the  $\Delta G$  values (kJ/mol) at 100 bars pressure and 25 °C for the transfer of enantiomer from the mobile phase to the stationary phase also had a similar trend: *S*(–)-metoprolol (–1.290)>*S*(–)-propranolol (–2.464)>*S*(–)-atenolol (–2.864)>*R*(+)-metoprolol (–3.989)>*R*(+)-atenolol (–4.120)>*R*(+)-propranolol (–4.800) (Table S4). These observation are in good agreement with the elution trend observed experimentally, *S*(–)-metoprolol (1.96 min)>*S*(–)-propranolol (2.59 min)>*S*(–)-atenolol (2.95 min)>*R*(+)-metoprolol (3.79 min)>*R*(+)-atenolol (4.05 min)>*R*(+)-propranolol (5.00 min) (Table S2). To further relate the binding energy with enantioselectivity, the difference in the binding energies of the enantiomers  $\Delta E_{R-S}$  (kJ/mol) was also evaluated. The absolute  $\Delta E_{R-S}$  values were 1.53, 1.36 and 0.63 kJ/mol for metoprolol, propranolol and atenolol, respectively. The largest difference of 1.53 kJ/mol for metoprolol indicates relatively easier separation of the enantiomers than propranolol or atenolol. These values can have direct correlation with the separation factor of the drug enantiomers, metoprolol (2.53 kJ/mol)>propranolol (2.33 kJ/mol)>atenolol (1.51 kJ/mol) (Table S2), which were found experimentally.

Further, chiral recognition mechanism can be understood from the 3D docking figures of enantiomers (Fig. 6). Appropriate fit of the enantiomers in the structure of CSP is paramount for chiral separation. The detailed information about each enantiomer is summarized in Table 3. As is apparent, hydrogen bonding and hydrophobic interactions were mainly responsible for enantioselectivity. *R*(+)-propranolol, the highly retained enantiomer under

the optimized experimental conditions, was bound with CSP through four hydrophobic interactions (bond lengths/distance 3.41–5.27 Å) and one hydrogen bond. Hydrophobic interactions were mainly generated from  $\pi$ -alkyl,  $\pi$ -sigma and  $\pi$ - $\pi$  stacking between the  $\pi$ -electrons of naphthyl ring in the enantiomer and the alkyl group or the  $\pi$ -electrons of the phenyl ring. On the other hand, *S*(–)-metoprolol which was the least retained had only two-point interaction with the CSP, via  $\pi$ -donor, H-bond and  $\pi$ -lone pair interaction. However, *R*(+)-metoprolol had greater retention due to two hydrogen bonds (between the hydrogen of –CO–CH<sub>3</sub> and CO of the –CO–NH– group) and three hydrophobic interactions involving  $\pi$ -alkyl and  $\pi$ -sigma bonding. Conventional hydrogen bonding was primarily responsible for the separation of atenolol enantiomers. The H-donor/acceptor was either the carbamoyl group of the enantiomer or carbamate group of the CSP (bond lengths/distance 2.84–3.25 Å).

Though it is difficult to comprehend the enantioselectivity and retention behavior solely based on molecular docking, nevertheless, the higher retention of *R*(+) enantiomers for the three  $\beta$ -blockers can be associated with a greater number of interactions with the CSP compared to the *S*(–) counterparts. Furthermore, comparison with reported work on these drugs using different chiral stationary phases shows some similarities as well as some variations. The work of Li et al. [22,23] on vancomycin-bonded and Chiralpak IB columns using HPLC showed *S*-enantiomers eluted first for some analytes which confers with the present work using Chiralpak<sup>®</sup> IG, while it was reverse with a similar column using SFC-MS/MS [32]. Additionally, the difference in the binding energies of the enantiomers as evaluated from simulation studies was the smallest for atenolol among the three  $\beta$ -blockers [23], which is comparable with the results obtained in the present work.

### 3.5. Comparison with reported work

Currently, the methods which deal with the simultaneous enantioselectivity and determination of atenolol, metoprolol and propranolol include capillary electrophoresis [15], HPLC [22,23], LC-MS/MS [24], and SFC-MS/MS [32]. The salient features of these methods are summarized in Table 4. However, all reported methods require separation time ranging from 10 to 35 min. In contrast, the present method allowed separation of all six enantiomers within

**Table 5**

Linear range and chromatographic characteristics of enantiomers of metoprolol, propranolol and atenolol.

Enantiomers	Linear range (µg/mL)	Slope (area response/ µg/mL) ± SD	Intercept (area response) ± SD	LOD (µg/mL)	LOQ (µg/mL)	Correlation coefficient ( $r^2$ )	Separation factor ( $\alpha$ )	Resolution factor ( $R_s$ )	Theoretical plates	Tailing factor
S(-)-metoprolol	0.5–10	160.42 ± 13.7	21.9 ± 6.12	0.126	0.381	0.9998	2.53	5.68	5232	1.12
R(+)-metoprolol	0.5–10	163.74 ± 12.6	22.5 ± 6.45	0.130	0.394	0.9995			8823	1.01
S(-)-propranolol	0.5–10	162.34 ± 11.4	22.4 ± 6.32	0.128	0.389	0.9997	2.33	6.83	6989	1.06
R(+)-propranolol	0.5–10	164.57 ± 14.2	22.8 ± 6.18	0.124	0.376	0.9996			9945	1.05
S(-)-atenolol	0.5–10	161.28 ± 12.8	22.2 ± 6.68	0.137	0.414	0.9995	1.51	3.48	7372	1.04
R(+)-atenolol	0.5–10	163.45 ± 15.5	22.6 ± 6.56	0.132	0.401	0.9999			11482	1.06

SD: standard deviation; LOD: limit of detection; LOQ: limit of quantitation.

6.0 min. Besides, a majority of reported procedures entailed large quantities of organic solvents for separation except one report using SFC-MS/MS [32]. Additionally, only two methods have discussed thermodynamic considerations, as well as molecular docking study to understand the interactions of the analytes with the chiral stationary phase [15,22]. Li et al. [23] investigated the chiral recognition mechanisms by molecular docking technique. Nevertheless, this was the first report on use of SFC technique for chiral separation which involves thermodynamics of drug interaction with the stationary phase and simulation study to understand the retention behavior of enantiomers. Furthermore, all the enantiomers were separated under identical elution conditions. In comparison to the existing procedures, the current method led to faster and more efficient separations while reducing development and validation time for chiral separation of these drugs.

### 3.6. Method validation results

The method was validated for linearity, limit of detection (LOD = 3.3  $\sigma/S$ , where  $\sigma$  is the standard deviation of the intercept and  $S$  the slope of the calibration lines), limit of quantitation (LOQ = 10  $\sigma/S$ ), specificity, intra-day and inter-day accuracy and precision and recovery following ICH guidelines [41]. For quantitative studies, a mixture of CO<sub>2</sub> and 0.1% isopropyl amine in isopropanol:methanol (50:50, V/V), in 75:25 (V/V) ratio was employed as the mobile phase. Although adequate resolution ( $R_s > 1.5$ ) of the enantiomers was possible with 5%–20% organic modifier, 25% was considered based on optimum analysis time, response, resolution and selectivity. The calibration curves were generated by plotting the peak area against the concentration of the enantiomers. The linearity (0.5–10 µg/mL,  $r^2 \geq 0.9995$ ) was established from five calibration lines by least square linear regression for each isomer.

The LOD and LOQ of the method were 0.126/0.381, 0.130/0.394, 0.128/0.389, 0.124/0.376, 0.137/0.414 and 0.132/0.401 µg/mL for S(-)-metoprolol, R(+)-metoprolol, S(-)-propranolol, R(+)-propranolol, S(-)-atenolol and R(+)-atenolol, respectively. The method specificity was determined by comparing the retention time of the standards and real samples (pharmaceutical formulations). The results showed good correlation in the measurement of retention time for all the enantiomers (% CV, 0.51–1.12). The detailed chromatographic characteristics are summarized in Table 5.

The results for intra-day and inter-day precision and accuracy of the method for all the enantiomers at three QC levels are summarized in Table S5. The intra-day and inter-day precision (% CV) ranged 1.2%–2.9% and 1.0%–2.9%, respectively. The accuracy (recovery) of the method was determined at 80%, 100%, and 120% of the claimed value by standard addition technique. The results showed good accuracy in the range of 98.63%–100.92% (Table S6).

### 3.7. Analysis of pharmaceuticals

The developed method was used to analyze these drugs in their commercial dosage forms. Fig. S2 shows the chromatograms of

enantioseparation of metoprolol, propranolol and atenolol from their tablet formulations. The results obtained showed acceptable accuracy and precision of the assay (Table S7). Moreover, there was no interference from the excipients present in the formulations. Further, the enantiomeric purity (or optical purity) of the separated analytes was also determined, S(-)-atenolol: 99.5%,  $[\alpha]_D^{25} = -24.2^\circ$  ( $c = 1.0$ , ethanol); R(+)-atenolol: 99.6%,  $[\alpha]_D^{25} = +24.4^\circ$  ( $c = 1.0$ , ethanol); S(-)-metoprolol: 99.4%,  $[\alpha]_D^{25} = -30.2^\circ$  ( $c = 1.0$ , ethanol); R(+)-metoprolol: 99.2%,  $[\alpha]_D^{25} = +29.9^\circ$  ( $c = 1.0$ , ethanol); S(-)-propranolol: 99.3%,  $[\alpha]_D^{25} = -21.9^\circ$  ( $c = 1.0$ , ethanol); and R(+)-propranolol: 99.5%,  $[\alpha]_D^{25} = +22.3^\circ$  ( $c = 1.0$ , ethanol).

To show the significance of the developed method, a statistical comparison of the results was made with reported methods [19,21] using  $t$ -test and  $F$ -test. The  $t$  and  $F$  values obtained were less than the tabulated values at four degrees of freedom, suggesting no significant difference between the two methods for any of the drugs.

## 4. Conclusions

Herein, we have described a new SFC method for enantioseparation of atenolol, metoprolol and propranolol on a chiral stationary phase using a single elution protocol. The influence of organic modifier and its proportion produced a greater effect on selectivity than the column temperature and back pressure. Although methanol and isopropanol were able to separate the enantiomers individually, a mixture of methanol and isopropanol provided the best conditions for their simultaneous separation in a single run with adequate resolution, selectivity and chromatographic efficiency. The thermodynamic data showed enthalpy driven separation for metoprolol and propranolol and entropy driven for atenolol. Molecular docking study substantiated the elution order of the enantiomers observed experimentally and also the mechanism for chiral recognition. Further, hydrogen bonding and hydrophobic interactions played a major role in enantioselectivity of the studied drugs. Finally, the SFC method was effectively applied to analyze commercially available formulations of these drugs.

### Declaration of competing interest

All authors declare that there are no conflicts of interest.

### Acknowledgments

The authors thank Department of Chemistry, Gujarat University, for supporting this work. One of the authors, Ms. Priyanka A. Shah, gratefully acknowledges Human Resource Development Group-Council of Scientific & Industrial Research (CSIR), New Delhi, for Research Associate Fellowship (File No.: 09/070(0058)2K18 EMR-I).

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jppha.2020.12.005>.

## References

- [1] T.J. Ward, K.D. Ward, Chiral separations: a review of current topics and trends, *Anal. Chem.* 84 (2012) 626–635.
- [2] C. West, Enantioselective separations with supercritical fluids—review, *Curr. Anal. Chem.* 10 (2014) 99–120.
- [3] D. Speybrouck, E. Lipka, Preparative Supercritical fluid chromatography: a powerful tool for chiral separations, *J. Chromatogr. A* 1467 (2016) 33–55.
- [4] FDA's policy statement for the development of new stereoisomeric drugs, *Chirality* 4 (1992) 338–340.
- [5] I. Ali, Z.A. Al-Othman, A. Al-Warthan, et al., Enantiomeric separation and simulation studies of pheniramine, oxybutynin, cetirizine, and brinzolamide chiral drugs on amylose-based columns, *Chirality* 26 (2014) 136–143.
- [6] J. Wu, X. Xiao, Z. Li, et al., Enantioseparation of chiral  $\beta$ -blockers using polynorepinephrine-coated nanoparticles and chiral capillary electrophoresis, *Anal. Bioanal. Chem.* 411 (2019) 2121–2129.
- [7] S. Alwera, R. Bhushan, Liquid chromatographic enantioseparation of three beta-adrenolytics using new derivatizing reagents synthesized from (S)-ketoprofen and confirmation of configuration of diastereomers, *Biomed. Chromatogr.* 30 (2016) 1772–1781.
- [8] P.S. Shrivastav, S.M. Buha, M. Sanyal, Detection and quantitation of  $\beta$ -blockers in plasma and urine, *Bioanalysis* 2 (2010) 263–276.
- [9] J. Agustian, A.H. Kamaruddin, H.Y. Aboul-Enein, Chromatographic comparison of atenolol separation in reaction media on cellulose tris-(3,5-dimethylphenylcarbamate) chiral stationary phase using ultra fast liquid chromatography, *Chirality* 24 (2012) 356–367.
- [10] R. Bhushan, C. Agarwal, Resolution of beta blocker enantiomers by TLC with vancomycin as impregnating agent or as chiral mobile phase Additive, *JPC-J. Planar. Chromatogr. – Mod. TLC* 23 (2010) 7–13.
- [11] E. Bodoki, M. Oltean, A. Bodoki, et al., Chiral recognition and quantification of propranolol enantiomers by surface enhanced Raman scattering through supramolecular interaction with  $\beta$ -cyclodextrin, *Talanta* 101 (2012) 53–58.
- [12] S. Tong, Y. Zheng, J. Yan, et al., Preparative enantioseparation of  $\beta$ -blocker drugs by counter-current chromatography using dialkyl L-tartrate as chiral selector based on borate coordination complex, *J. Chromatogr. A* 1263 (2012) 74–83.
- [13] J.M. Park, J.H. Park, Enantiomer separations of basic chiral compounds by capillary electrochromatography on a phosphated  $\beta$ -cyclodextrin-modified zirconia monolith, *J. Chromatogr. A* 1339 (2014) 229–233.
- [14] X. Sun, Y. Du, S. Zhao, et al., Enantioseparation of propranolol, amlodipine and metoprolol by electrochromatography using an open tubular capillary modified with  $\beta$ -cyclodextrin and poly (glycidyl methacrylate) nanoparticles, *Mikrochim. Acta* 186 (2019), 128.
- [15] W. Li, C. Liu, G. Tan, et al., Molecular modeling study of chiral separation and recognition mechanism of  $\beta$ -adrenergic antagonists by capillary electrophoresis, *Int. J. Mol. Sci.* 13 (2012) 710–725.
- [16] S.Q. Hu, W.J. Lü, Y.H. Ma, et al., Chiral separation of  $\beta$ -blockers by MEEKC using neutral microemulsion: analysis of separation mechanism and further elucidation of resolution equation, *Electrophoresis* 34 (2013) 260–268.
- [17] S. Dixit, J.H. Park, Application of rifampicin as a chiral selector for enantio-resolution of basic drugs using capillary electrophoresis, *J. Chromatogr. A* 1453 (2016) 138–142.
- [18] L. Fang, Y. Du, X. Hu, et al., Carboxymethyl  $\beta$ -cyclodextrin as chiral selector in capillary electrophoresis: enantioseparation of 16 basic chiral drugs and its chiral recognition mechanism associated with drugs' structural features, *Biomed. Chromatogr.* 31 (2017), e3991.
- [19] A.K. Singh, E.R.M. Kedor-Hackmann, M.I.R.M. Santoro, Development and validation of a chiral liquid chromatographic method for the determination of atenolol and metoprolol enantiomers in tablet preparations, *J. AOAC Int.* 84 (2001) 1724–1729.
- [20] I. Ali, V.D. Gaitonde, H.Y. Aboul-Enein, et al., Chiral separation of  $\beta$ -adrenergic blockers on CelluCoat column by HPLC, *Talanta* 78 (2009) 458–463.
- [21] D. Wang, F. Li, Z. Jiang, et al., Chiral recognition mechanisms of four  $\beta$ -blockers by HPLC with amylose chiral stationary phase, *Iran, J. Pharm. Res.* 13 (2014) 449–457.
- [22] J. Li, R. Liu, L. Wang, et al., Enantioseparation of chiral pharmaceuticals by vancomycin-bonded stationary phase and analysis of chiral recognition mechanism, *Chirality* 31 (2019) 236–247.
- [23] M. Li, Z. Jiang, X. Di, et al., Enantiomeric separation of six beta-adrenergic blockers on Chiralpak IB column and identification of chiral recognition mechanisms by molecular docking technique, *Biomed. Chromatogr.* 5 (2020), e4803.
- [24] L.N. Nikolai, E.L. McClure, S.L. MacLeod, et al., Stereoisomer quantification of the  $\beta$ -blocker drugs atenolol, metoprolol, and propranolol in wastewaters by chiral high-performance liquid chromatography–tandem mass spectrometry, *J. Chromatogr. A* 1131 (2006) 103–109.
- [25] V.K.H. Barclay, N.L. Tyrefors, I.M. Johansson, et al., Chiral analysis of metoprolol and two of its metabolites,  $\alpha$ -hydroxymetoprolol and deaminated metoprolol, in wastewater using liquid chromatography–tandem mass spectrometry, *J. Chromatogr. A* 1269 (2012) 208–217.
- [26] N. De J. Antunes, R.C. Cavalli, M.P. Marques, et al., Stereoselective determination of metoprolol and its metabolite  $\alpha$ -hydroxymetoprolol in plasma by LC-MS/MS: application to pharmacokinetics during pregnancy, *Chirality* 25 (2013) 1–7.
- [27] P. Sharma, P. Contractor, S. Guttikar, et al., Development of a sensitive and rapid method for quantitation of (S)-(-) and (R)-(+)-metoprolol in human plasma by chiral LC–ESI–MS/MS, *J. Pharm. Anal.* 4 (2014) 63–79.
- [28] I. Baranowska, W. Adolf, S. Magiera, Enantioselective determination of metoprolol and its metabolites in human urine high-performance liquid chromatography with fluorescence detection (HPLC–FLD) and tandem mass spectrometry(MS/MS), *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 1004 (2015) 79–84.
- [29] H. Elmongy, H. Ahmed, A.A. Wahbi, et al., Determination of metoprolol enantiomers in human plasma and saliva samples utilizing microextraction by packed sorbent and liquid chromatography–tandem mass spectrometry, *Biomed. Chromatogr.* 30 (2016) 1309–1317.
- [30] J. Chen, Y. Hsieh, J. Cook, et al., Supercritical fluid chromatography–tandem mass spectrometry for the enantioselective determination of propranolol and pindolol in mouse blood by serial sampling, *Anal. Chem.* 78 (2006) 1212–1217.
- [31] M.K. Parr, B. Wuest, E. Naegel, et al., SFC-MS/MS as an orthogonal technique for improved screening of polar analytes in anti-doping control, *Anal. Bioanal. Chem.* 408 (2016) 6789–6797.
- [32] A. Svan, M. Hedeland, T. Arvidsson, et al., Rapid chiral separation of atenolol, metoprolol, propranolol and the zwitterionic metoprolol acid using supercritical fluid chromatography–tandem mass spectrometry—Application to wetland microcosms, *J. Chromatogr. A* 1409 (2015) 251–258.
- [33] K. Kalíková, M. Martínková, M.G. Schmid, et al., Cellulose tris-(3,5-dimethylphenylcarbamate)-based chiral stationary phase for the enantioseparation of drugs in supercritical fluid chromatography: comparison with HPLC, *J. Sep. Sci.* 41 (2018) 1471–1478.
- [34] W. Ren-Qi, O. Teng-Teng, N. Siu-Choon, et al., Recent advances in pharmaceutical separations with supercritical fluid chromatography using chiral stationary phases, *TrAC Trends Anal. Chem.* 37 (2012) 83–100.
- [35] C. West, Recent trends in chiral supercritical fluid chromatography, *TrAC Trends Anal. Chem.* 120 (2019), 115648.
- [36] L. Nováková, M. Douša, General screening and optimization strategy for fast chiral separations in modern supercritical fluid chromatography, *Anal. Chim. Acta* 950 (2017) 199–210.
- [37] M.F. Sanner, Python: a programming language for software integration and development, *J. Mol. Graph. Model* 17 (1999) 57–61.
- [38] G.M. Morris, D.S. Goodsell, R.S. Halliday, et al., Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, *J. Comput. Chem.* 19 (1998) 1639–1662.
- [39] C. West, A. Bouet, S. Routier, et al., Effects of mobile phase composition and temperature on the supercritical fluid chromatography enantioseparation of chiral fluoro-oxindole-type compounds with chlorinated polysaccharide stationary phases, *J. Chromatogr. A* 1269 (2012) 325–335.
- [40] L. Nováková, M. Douša, J.L. Bernal, M.T. Martín, et al., Effects of organic modifier and temperature on the enantiomeric separation of several azole drugs using supercritical fluid chromatography and the Chiralpak AD column, *Biomed. Chromatogr.* 28 (2014) 152–158.
- [41] International Conference on Harmonisation, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline Q2(R1): Validation of Analytical Procedures: Text and Methodology Q2(R1), Geneva, Switzerland, 2005.